New Research Coverage Highlights Fortive, Pieris Pharmaceuticals, CEVA, ManTech International, Cerus, and NN — Consolidated Revenues, Company Growth, and Expectations for 2019 - CEVA (NASDAQ:CEVA), Cerus (NASDAQ:CERS)

NEW YORK, April 10, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Fortive Corporation FTV, Pieris Pharmaceuticals, Inc. PIRS, CEVA, Inc. CEVA, ManTech International Corporation MANT, Cerus Corporation CERS, and NN, Inc. NNBR, including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.

Complimentary Access: Research Reports

Full copies of recently published reports are available to readers at the links below.

FTV DOWNLOAD: http://Fundamental-Markets.com/register/?so=FTV
PIRS DOWNLOAD: http://Fundamental-Markets.com/register/?so=PIRS
CEVA DOWNLOAD: http://Fundamental-Markets.com/register/?so=CEVA
MANT DOWNLOAD: http://Fundamental-Markets.com/register/?so=MANT
CERS DOWNLOAD: http://Fundamental-Markets.com/register/?so=CERS
NNBR DOWNLOAD: http://Fundamental-Markets.com/register/?so=NNBR

(You may have to copy and paste the link into your browser and hit the [ENTER] key)

The new research reports from Fundamental Markets, available for free download at the links above, examine Fortive Corporation FTV, Pieris Pharmaceuticals, Inc. PIRS, CEVA, Inc. CEVA, ManTech International Corporation MANT, Cerus Corporation CERS, and NN, Inc. NNBR on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.

-----------------------------------------

Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.

-----------------------------------------

FORTIVE CORPORATION (FTV) REPORT OVERVIEW

Fortive's Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, Fortive reported revenue of $1,015.90MM vs $906.80MM (up 12.03%) and analysts estimated basic earnings per share $6.09 vs $0.97 (up 527.84%). For the twelve months ended December 31st, 2018 vs December 31st, 2017, Fortive reported revenue of $6,452.70MM vs $5,756.10MM (up 12.10%) and analysts estimated basic earnings per share $8.33 vs $3.01 (up 176.74%). Analysts expect earnings to be released on April 25th, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was $0.78. The estimated EPS forecast for the next fiscal year is $3.93 and is expected to report on February 6th, 2020.

To read the full Fortive Corporation (FTV) report, download it here: http://Fundamental-Markets.com/register/?so=FTV

-----------------------------------------

PIERIS PHARMACEUTICALS, INC. (PIRS) REPORT OVERVIEW

Pieris Pharmaceuticals' Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, Pieris Pharmaceuticals reported revenue of $4.91MM vs $18.15MM (down 72.93%) and analysts estimated basic earnings per share -$0.22 vs $0.18. For the twelve months ended December 31st, 2018 vs December 31st, 2017, Pieris Pharmaceuticals reported revenue of $29.10MM vs $25.28MM (up 15.14%) and analysts estimated basic earnings per share -$0.50 vs -$0.40. Analysts expect earnings to be released on May 9th, 2019. The report will be for the fiscal period ending March 31st, 2019. Reported EPS for the same quarter last year was -$0.17. The estimated EPS forecast for the next fiscal year is -$1.16 and is expected to report on March 16th, 2020.

To read the full Pieris Pharmaceuticals, Inc. (PIRS) report, download it here: http://Fundamental-Markets.com/register/?so=PIRS

-----------------------------------------

CEVA, INC. (CEVA) REPORT OVERVIEW

CEVA's Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, CEVA reported revenue of $21.40MM vs $21.60MM (down 0.93%) and analysts estimated basic earnings per share $0.10 vs $0.14 (down 28.57%). For the twelve months ended December 31st, 2018 vs December 31st, 2017, CEVA reported revenue of $77.88MM vs $87.51MM (down 11.00%) and analysts estimated basic earnings per share $0.03 vs $0.78 (down 96.15%). Analysts expect earnings to be released on May 6th, 2019. The report will be for the fiscal period ending March 31st, 2019. Reported EPS for the same quarter last year was -$0.08. The estimated EPS forecast for the next fiscal year is $0.30 and is expected to report on February 12th, 2020.

To read the full CEVA, Inc. (CEVA) report, download it here: http://Fundamental-Markets.com/register/?so=CEVA

-----------------------------------------

MANTECH INTERNATIONAL CORPORATION (MANT) REPORT OVERVIEW

ManTech International's Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, ManTech International reported revenue of $497.07MM vs $462.28MM (up 7.53%) and basic earnings per share $0.52 vs $1.76 (down 70.45%). For the twelve months ended December 31st, 2018 vs December 31st, 2017, ManTech International reported revenue of $1,958.56MM vs $1,717.02MM (up 14.07%) and analysts estimated basic earnings per share $2.08 vs $2.94 (down 29.25%). Analysts expect earnings to be released on May 1st, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was $0.51. The estimated EPS forecast for the next fiscal year is $2.49 and is expected to report on February 19th, 2020.

To read the full ManTech International Corporation (MANT) report, download it here: http://Fundamental-Markets.com/register/?so=MANT

-----------------------------------------

CERUS CORPORATION (CERS) REPORT OVERVIEW

Cerus' Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, Cerus reported revenue of $20.24MM vs $18.62MM (up 8.70%) and analysts estimated basic earnings per share -$0.12 vs -$0.10. For the twelve months ended December 31st, 2018 vs December 31st, 2017, Cerus reported revenue of $76.05MM vs $51.33MM (up 48.17%) and analysts estimated basic earnings per share -$0.44 vs -$0.56. Analysts expect earnings to be released on May 14th, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was -$0.11. The estimated EPS forecast for the next fiscal year is -$0.30 and is expected to report on February 25th, 2020.

To read the full Cerus Corporation (CERS) report, download it here: http://Fundamental-Markets.com/register/?so=CERS

-----------------------------------------

NN, INC. (NNBR) REPORT OVERVIEW

NN's Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, NN reported revenue of $199.48MM vs $156.14MM (up 27.76%) and analysts estimated basic earnings per share -$6.76 vs $1.87. For the twelve months ended December 31st, 2018 vs December 31st, 2017, NN reported revenue of $770.66MM vs $619.79MM (up 24.34%) and analysts estimated basic earnings per share -$8.35 vs $5.94. Analysts expect earnings to be released on May 8th, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was $0.32. The estimated EPS forecast for the next fiscal year is $1.43 and is expected to report on March 11th, 2020.

To read the full NN, Inc. (NNBR) report, download it here: http://Fundamental-Markets.com/register/?so=NNBR

-----------------------------------------

ABOUT FUNDAMENTAL MARKETS

Fundamental Markets serves thousands of members and have provided research through some of the world's leading brokerages for over a decade–and continue to be one of the best information sources for investors and investment professionals worldwide. Fundamental Markets' roster boasts decades of financial experience and includes top financial writers, FINRA® BrokerCheck® certified professionals with current and valid CRD® number designations, as well as Chartered Financial Analyst® (CFA®) designation holders, to ensure up to date factual information for active readers on the topics they care about.

REGISTERED MEMBER STATUS

Fundamental Markets' oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Fundamental Markets' roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Fundamental Markets have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Fundamental Markets' Compliance department by Phone, at +1 667-401-0010, or by E-mail at compliance@Fundamental-Markets.com.

LEGAL NOTICES

Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Fundamental Markets, Fundamental Markets members, and/or Fundamental Markets affiliates are not responsible for any gains or losses that result from the opinions expressed. Fundamental Markets makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Fundamental Markets has not been compensated for the publication of this press release by any of the above mentioned companies. Fundamental Markets is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.

Media Contact:
Arden Dalio, Media Department
Office: +1 667-401-0010
E-mail: media@Fundamental-Markets.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.

Market News and Data brought to you by Benzinga APIs